WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals (LGND) announced the launch of
Pelthos Therapeutics, a biopharmaceutical company. Pelthos is a wholly owned
subsidiary of Ligand. Pelthos is committed to commercializing therapeutic
products to help patients impacted by diseases with limited treatment options.
The company's lead product is ZELSUVMI topical gel, 10.3%, for the treatment of
molluscum contagiosum in adults and pediatric patients one year of age and
older. ZELSUVMI is expected to be available in the U.S. in late 2024.

Also, Ligand Pharmaceuticals announced the appointment of Scott Plesha to the
role of Chief Executive Officer. Prior to joining Pelthos, Plesha was President
and Chief Commercial Officer at BioDelivery Sciences until it was acquired by
Collegium Pharmaceutical in 2022.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX